Haemonetics Receives FDA Clearance For Expanded Use Of TEG® 6s Hemostasis Analyzer System In Adult Trauma Settings
The 510(k) clearance was based on clinical data from a multicenter, multistate trial of approximately 500 adult patients comparing the TEG® 5000 Hemostasis Analyzer System, which has been used in trauma for over a decade, to the next-generation TEG 6s system. The study collected more than 150,000 data points and showed that the TEG 6s system is reliable, substantially and analytically equivalent and test results can be interpreted like those from the TEG 5000 system when used in a trauma setting.
The TEG 6s system, comprised of the analyzer, disposable cartridges and software, provides rapid, comprehensive and accurate identification of a patient's hemostasis condition. Featuring an innovative, all-in-one cartridge, the TEG 6s system delivers viscoelastic test results without the complicated test preparation associated with traditional blood tests. The cartridge automatically mixes a small blood sample with reagents and runs up to four assays in parallel, lowering the potential for human error, allowing immediate test initiation and significantly reducing wait time for results so clinicians can quickly tailor treatment to a patient's specific needs.
"The TEG 6s system brings a new level of simplicity, consistency and speed to the coagulation testing process when every moment counts," said
"The TEG 6s analyzer is an important tool for trauma centers needing fast access to information about critically injured patients," said
About
Investor Contact: |
Media Contact: |
Gerry Gould, VP-Investor Relations |
Carla Burigatto, VP-Communications |
(781) 356-9402 |
(781) 348-7263 |
Olga Vlasova, Sr. Mgr.-Investor Relations |
|
(781) 356-9763 |
|
View original content to download multimedia:http://www.prnewswire.com/news-releases/haemonetics-receives-fda-clearance-for-expanded-use-of-teg-6s-hemostasis-analyzer-system-in-adult-trauma-settings-300849293.html
SOURCE